7dfp: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==== | ==Human dopamine D2 receptor in complex with spiperone== | ||
<StructureSection load='7dfp' size='340' side='right'caption='[[7dfp]]' scene=''> | <StructureSection load='7dfp' size='340' side='right'caption='[[7dfp]], [[Resolution|resolution]] 3.10Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id= OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[7dfp]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli], [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7DFP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7DFP FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.1Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=SIP:8-[4-(4-fluorophenyl)-4-oxidanylidene-butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one'>SIP</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7dfp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7dfp OCA], [https://pdbe.org/7dfp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7dfp RCSB], [https://www.ebi.ac.uk/pdbsum/7dfp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7dfp ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Disease == | |||
[https://www.uniprot.org/uniprot/DRD2_HUMAN DRD2_HUMAN] Myoclonic dystonia 11. The gene represented in this entry may be involved in disease pathogenesis. DRD2 mutations in myoclonic dystonia patients are rare, and their contribution to disease phenotype is unclear (PubMed:10716258). | |||
== Function == | |||
[https://www.uniprot.org/uniprot/C562_ECOLX C562_ECOLX] Electron-transport protein of unknown function.[https://www.uniprot.org/uniprot/DRD2_HUMAN DRD2_HUMAN] Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (By similarity).<ref>PMID:21645528</ref> <ref>PMID:17264214</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
In addition to the serotonin 5-HT(2A) receptor (5-HT(2A)R), the dopamine D(2) receptor (D(2)R) is a key therapeutic target of antipsychotics for the treatment of schizophrenia. The inactive state structures of D(2)R have been described in complex with the inverse agonists risperidone (D(2)R(ris)) and haloperidol (D(2)R(hal)). Here we describe the structure of human D(2)R in complex with spiperone (D(2)R(spi)). In D(2)R(spi), the conformation of the extracellular loop (ECL) 2, which composes the ligand-binding pocket, was substantially different from those in D(2)R(ris) and D(2)R(hal), demonstrating that ECL2 in D(2)R is highly dynamic. Moreover, D(2)R(spi) exhibited an extended binding pocket to accommodate spiperone's phenyl ring, which probably contributes to the selectivity of spiperone to D(2)R and 5-HT(2A)R. Together with D(2)R(ris) and D(2)R(hal), the structural information of D(2)R(spi) should be of value for designing novel antipsychotics with improved safety and efficacy. | |||
Structure of the dopamine D(2) receptor in complex with the antipsychotic drug spiperone.,Im D, Inoue A, Fujiwara T, Nakane T, Yamanaka Y, Uemura T, Mori C, Shiimura Y, Kimura KT, Asada H, Nomura N, Tanaka T, Yamashita A, Nango E, Tono K, Kadji FMN, Aoki J, Iwata S, Shimamura T Nat Commun. 2020 Dec 22;11(1):6442. doi: 10.1038/s41467-020-20221-0. PMID:33353947<ref>PMID:33353947</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 7dfp" style="background-color:#fffaf0;"></div> | |||
==See Also== | |||
*[[Antibody 3D structures|Antibody 3D structures]] | |||
*[[Dopamine receptor 3D structures|Dopamine receptor 3D structures]] | |||
== References == | |||
<references/> | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Escherichia coli]] | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: | [[Category: Mus musculus]] | ||
[[Category: Im D]] | |||
[[Category: Iwata S]] | |||
[[Category: Shimamura T]] | |||
Latest revision as of 13:05, 6 September 2023
Human dopamine D2 receptor in complex with spiperoneHuman dopamine D2 receptor in complex with spiperone
Structural highlights
DiseaseDRD2_HUMAN Myoclonic dystonia 11. The gene represented in this entry may be involved in disease pathogenesis. DRD2 mutations in myoclonic dystonia patients are rare, and their contribution to disease phenotype is unclear (PubMed:10716258). FunctionC562_ECOLX Electron-transport protein of unknown function.DRD2_HUMAN Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase (By similarity).[1] [2] Publication Abstract from PubMedIn addition to the serotonin 5-HT(2A) receptor (5-HT(2A)R), the dopamine D(2) receptor (D(2)R) is a key therapeutic target of antipsychotics for the treatment of schizophrenia. The inactive state structures of D(2)R have been described in complex with the inverse agonists risperidone (D(2)R(ris)) and haloperidol (D(2)R(hal)). Here we describe the structure of human D(2)R in complex with spiperone (D(2)R(spi)). In D(2)R(spi), the conformation of the extracellular loop (ECL) 2, which composes the ligand-binding pocket, was substantially different from those in D(2)R(ris) and D(2)R(hal), demonstrating that ECL2 in D(2)R is highly dynamic. Moreover, D(2)R(spi) exhibited an extended binding pocket to accommodate spiperone's phenyl ring, which probably contributes to the selectivity of spiperone to D(2)R and 5-HT(2A)R. Together with D(2)R(ris) and D(2)R(hal), the structural information of D(2)R(spi) should be of value for designing novel antipsychotics with improved safety and efficacy. Structure of the dopamine D(2) receptor in complex with the antipsychotic drug spiperone.,Im D, Inoue A, Fujiwara T, Nakane T, Yamanaka Y, Uemura T, Mori C, Shiimura Y, Kimura KT, Asada H, Nomura N, Tanaka T, Yamashita A, Nango E, Tono K, Kadji FMN, Aoki J, Iwata S, Shimamura T Nat Commun. 2020 Dec 22;11(1):6442. doi: 10.1038/s41467-020-20221-0. PMID:33353947[3] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||